drugset / Trial / NCT03919929

Treating PCOS With Semaglutide vs Active Lifestyle Intervention

NCT03919929

RandomizedParallel-groupOpen-labelTreatment

Summary

Girls with obesity and polycystic ovarian syndrome will receive either glucagon like peptide-1 receptor agonist therapy or a dietary intervention for 12 weeks to decrease the metabolic syndrome, in particular to lower hepatic fat and improve insulin sensitivity.

Timeline

Start
2019-05-03
Primary completion
2023-10-03
Completion
2023-10-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Semaglutide Peptide 3 mg Oral
Subject Semaglutide Peptide 7 mg Oral